Clinical Trial Update: Phase 2 Study of KHK7580 [Phase 2]

View source ↗

Summary

Phase 2 study of KHK7580 for secondary hyperparathyroidism has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperparathyroidism

Drugs mentioned

• KHK7580

Snippet

Sponsor: Kyowa Kirin Co., Ltd. | Conditions: Secondary Hyperparathyroidism | Phase 2 | Status: COMPLETED